Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · S

S. 1801 (116th)

Affordable Medications Act

referredUnited States· United States Congress· EN

Introduced

12 June 2019

Last action

12 June 2019 · Introduced

Status

Read twice and referred to the Committee on Finance.

Sponsors

Sen. Smith, Tina [D-MN], Sen. Klobuchar, Amy [D-MN], Sen. Blumenthal, Richard [D-CT], Sen. Udall, Tom [D-NM], Sen. Brown, Sherrod [D-OH], Sen. Warren, Elizabeth [D-MA], Sen. Sanders, Bernard [I-VT], Sen. Hassan, Margaret Wood [D-NH], Sen. Whitehouse, Sheldon [D-RI], Sen. Merkley, Jeff [D-OR], Sen. Reed, Jack [D-RI], Sen. Baldwin, Tammy [D-WI], Sen. Booker, Cory A. [D-NJ], Sen. Durbin, Richard J. [D-IL], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Harris, Kamala D. [D-CA]

Subjects

Healthcare, Taxation

Source updated

3 January 2025

Healthcare · Taxation

Summary

Affordable Medications Act This bill revises and expands various requirements relating to prescription-drug pricing and affordability. Specifically, the bill expands financial reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under Medicare; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans and group health plans; modifies requirements for the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; limits the time frame that trade agreements are required to provide market exclusivity for biological products; establishes an innovation incentive fund for new or more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; revises certain time frames and conditions related to drug exclusivity; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, disclosure of wholesale acquisition prices, and patent-infringement proceedings.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 12 June 2019

    Introduced

    Read twice and referred to the Committee on Finance.

    Source: IntroReferral

  2. 12 June 2019

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in Senate (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate (text)

    Introduced in Senate · EN · 12 June 2019

    ViewDownloadOpen at official source

  • Introduced in Senate (PDF)

    Introduced in Senate · EN · 12 June 2019

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in Senate

    summary · EN · 12 June 2019

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Showing 10 of 12 related records.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.